In­cyte’s PD-(L)1 in­hibitor head­ed for an ODAC show­down next month

The FDA’s On­co­log­ic Drugs Ad­vi­so­ry Com­mit­tee will spend a half day on June 24 re­view­ing In­cyte’s PD-(L)1 in­hibitor reti­fan­limab as a treat­ment for lo­cal­ly ad­vanced or metasta­t­ic squa­mous car­ci­no­ma of the anal canal (SCAC) for those who have pro­gressed on or who are in­tol­er­ant of plat­inum-based chemother­a­py.

The eighth PD-(L)1 en­trant in Jan­u­ary nabbed a pri­or­i­ty re­view and an or­phan des­ig­na­tion from the FDA, which sets the agency’s fi­nal de­ci­sion date as Ju­ly 25.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.